BIOMARIN PHARMACEUTICAL INC (BMRN) Stock Fundamental Analysis
NASDAQ:BMRN • US09061G1013
61.73 USD
+0.62 (+1.01%)
At close: Feb 27, 2026
59.3099 USD
-2.42 (-3.92%)
After Hours: 2/27/2026, 8:00:02 PM
Overall BMRN gets a fundamental rating of 7 out of 10. We evaluated BMRN against 520 industry peers in the Biotechnology industry. BMRN scores excellent points on both the profitability and health parts. This is a solid base for a good stock. BMRN may be a bit undervalued, certainly considering the very reasonable score on growth These ratings could make BMRN a good candidate for value and quality investing.
1. Profitability
1.1 Basic Checks
- BMRN had positive earnings in the past year.
- BMRN had a positive operating cash flow in the past year.
- BMRN had positive earnings in 4 of the past 5 years.
- Each year in the past 5 years BMRN had a positive operating cash flow.
1.2 Ratios
- The Return On Assets of BMRN (6.83%) is better than 92.53% of its industry peers.
- Looking at the Return On Equity, with a value of 8.59%, BMRN belongs to the top of the industry, outperforming 92.15% of the companies in the same industry.
- The Return On Invested Capital of BMRN (6.93%) is better than 93.10% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for BMRN is significantly below the industry average of 17.87%.
- The 3 year average ROIC (5.53%) for BMRN is below the current ROIC(6.93%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.83% | ||
| ROE | 8.59% | ||
| ROIC | 6.93% |
ROA(3y)4.38%
ROA(5y)2.86%
ROE(3y)5.55%
ROE(5y)3.65%
ROIC(3y)5.53%
ROIC(5y)N/A
1.3 Margins
- Looking at the Profit Margin, with a value of 16.82%, BMRN belongs to the top of the industry, outperforming 92.53% of the companies in the same industry.
- BMRN's Profit Margin has declined in the last couple of years.
- Looking at the Operating Margin, with a value of 20.21%, BMRN belongs to the top of the industry, outperforming 94.25% of the companies in the same industry.
- In the last couple of years the Operating Margin of BMRN has grown nicely.
- With an excellent Gross Margin value of 81.32%, BMRN belongs to the best of the industry, outperforming 85.44% of the companies in the same industry.
- BMRN's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.21% | ||
| PM (TTM) | 16.82% | ||
| GM | 81.32% |
OM growth 3Y88.74%
OM growth 5YN/A
PM growth 3Y17.04%
PM growth 5Y-25.17%
GM growth 3Y1.91%
GM growth 5Y2.54%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BMRN is destroying value.
- BMRN has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, BMRN has more shares outstanding
- BMRN has a better debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 5.76 indicates that BMRN is not in any danger for bankruptcy at the moment.
- BMRN has a Altman-Z score of 5.76. This is in the better half of the industry: BMRN outperforms 73.95% of its industry peers.
- BMRN has a debt to FCF ratio of 0.72. This is a very positive value and a sign of high solvency as it would only need 0.72 years to pay back of all of its debts.
- The Debt to FCF ratio of BMRN (0.72) is better than 94.64% of its industry peers.
- BMRN has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
- BMRN's Debt to Equity ratio of 0.10 is on the low side compared to the rest of the industry. BMRN is outperformed by 62.26% of its industry peers.
- Although BMRN does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.72 | ||
| Altman-Z | 5.76 |
ROIC/WACC0.83
WACC8.38%
2.3 Liquidity
- A Current Ratio of 4.83 indicates that BMRN has no problem at all paying its short term obligations.
- BMRN has a Current ratio (4.83) which is in line with its industry peers.
- BMRN has a Quick Ratio of 3.10. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.
- With a Quick ratio value of 3.10, BMRN is not doing good in the industry: 61.49% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.83 | ||
| Quick Ratio | 3.1 |
3. Growth
3.1 Past
- BMRN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.22%, which is quite good.
- The earnings per share for BMRN have been decreasing by -11.43% on average. This is quite bad
- Looking at the last year, BMRN shows a quite strong growth in Revenue. The Revenue has grown by 12.87% in the last year.
- The Revenue has been growing by 11.60% on average over the past years. This is quite good.
EPS 1Y (TTM)12.22%
EPS 3Y104.5%
EPS 5Y-11.43%
EPS Q2Q%-28.12%
Revenue 1Y (TTM)12.87%
Revenue growth 3Y15.4%
Revenue growth 5Y11.6%
Sales Q2Q%17.03%
3.2 Future
- BMRN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.55% yearly.
- Based on estimates for the next years, BMRN will show a small growth in Revenue. The Revenue will grow by 6.54% on average per year.
EPS Next Y78.78%
EPS Next 2Y47.79%
EPS Next 3Y40.96%
EPS Next 5Y23.55%
Revenue Next Year10.4%
Revenue Next 2Y9.83%
Revenue Next 3Y6.78%
Revenue Next 5Y6.54%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 24.89, BMRN is valued on the expensive side.
- 92.91% of the companies in the same industry are more expensive than BMRN, based on the Price/Earnings ratio.
- The average S&P500 Price/Earnings ratio is at 27.07. BMRN is around the same levels.
- With a Price/Forward Earnings ratio of 13.92, BMRN is valued correctly.
- BMRN's Price/Forward Earnings ratio is rather cheap when compared to the industry. BMRN is cheaper than 96.17% of the companies in the same industry.
- BMRN is valuated cheaply when we compare the Price/Forward Earnings ratio to 28.05, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.89 | ||
| Fwd PE | 13.92 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, BMRN is valued cheaply inside the industry as 95.02% of the companies are valued more expensively.
- 97.13% of the companies in the same industry are more expensive than BMRN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.36 | ||
| EV/EBITDA | 15.18 |
4.3 Compensation for Growth
- BMRN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- BMRN has an outstanding profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as BMRN's earnings are expected to grow with 40.96% in the coming years.
PEG (NY)0.32
PEG (5Y)N/A
EPS Next 2Y47.79%
EPS Next 3Y40.96%
5. Dividend
5.1 Amount
- BMRN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
61.73
+0.62 (+1.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-23 2026-02-23/amc
Earnings (Next)04-29 2026-04-29/amc
Inst Owners97.82%
Inst Owner Change4.68%
Ins Owners0.64%
Ins Owner Change-0.25%
Market Cap11.86B
Revenue(TTM)3.22B
Net Income(TTM)520.42M
Analysts81.25
Price Target92.49 (49.83%)
Short Float %4.15%
Short Ratio3.18
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-48.87%
Min EPS beat(2)-142.18%
Max EPS beat(2)44.44%
EPS beat(4)3
Avg EPS beat(4)-11.96%
Min EPS beat(4)-142.18%
Max EPS beat(4)44.44%
EPS beat(8)6
Avg EPS beat(8)2.48%
EPS beat(12)9
Avg EPS beat(12)14.79%
EPS beat(16)12
Avg EPS beat(16)-9.32%
Revenue beat(2)1
Avg Revenue beat(2)1.98%
Min Revenue beat(2)-2.53%
Max Revenue beat(2)6.48%
Revenue beat(4)2
Avg Revenue beat(4)1.32%
Min Revenue beat(4)-2.53%
Max Revenue beat(4)6.48%
Revenue beat(8)4
Avg Revenue beat(8)1.53%
Revenue beat(12)5
Avg Revenue beat(12)0.37%
Revenue beat(16)7
Avg Revenue beat(16)0.03%
PT rev (1m)-1%
PT rev (3m)-1.71%
EPS NQ rev (1m)3.58%
EPS NQ rev (3m)-29.4%
EPS NY rev (1m)-4.52%
EPS NY rev (3m)-1.63%
Revenue NQ rev (1m)0.07%
Revenue NQ rev (3m)0.3%
Revenue NY rev (1m)0.65%
Revenue NY rev (3m)2.88%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.89 | ||
| Fwd PE | 13.92 | ||
| P/S | 3.83 | ||
| P/FCF | 14.36 | ||
| P/OCF | 12.98 | ||
| P/B | 1.96 | ||
| P/tB | 2.11 | ||
| EV/EBITDA | 15.18 |
EPS(TTM)2.48
EY4.02%
EPS(NY)4.43
Fwd EY7.18%
FCF(TTM)4.3
FCFY6.96%
OCF(TTM)4.76
OCFY7.71%
SpS16.11
BVpS31.53
TBVpS29.29
PEG (NY)0.32
PEG (5Y)N/A
Graham Number41.94
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.83% | ||
| ROE | 8.59% | ||
| ROCE | 9.17% | ||
| ROIC | 6.93% | ||
| ROICexc | 8.85% | ||
| ROICexgc | 9.62% | ||
| OM | 20.21% | ||
| PM (TTM) | 16.82% | ||
| GM | 81.32% | ||
| FCFM | 26.69% |
ROA(3y)4.38%
ROA(5y)2.86%
ROE(3y)5.55%
ROE(5y)3.65%
ROIC(3y)5.53%
ROIC(5y)N/A
ROICexc(3y)6.73%
ROICexc(5y)N/A
ROICexgc(3y)7.34%
ROICexgc(5y)N/A
ROCE(3y)7.33%
ROCE(5y)N/A
ROICexgc growth 3Y103.37%
ROICexgc growth 5YN/A
ROICexc growth 3Y106.5%
ROICexc growth 5YN/A
OM growth 3Y88.74%
OM growth 5YN/A
PM growth 3Y17.04%
PM growth 5Y-25.17%
GM growth 3Y1.91%
GM growth 5Y2.54%
F-Score7
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.72 | ||
| Debt/EBITDA | 0.84 | ||
| Cap/Depr | 106.6% | ||
| Cap/Sales | 2.85% | ||
| Interest Coverage | 85.91 | ||
| Cash Conversion | 129.08% | ||
| Profit Quality | 158.68% | ||
| Current Ratio | 4.83 | ||
| Quick Ratio | 3.1 | ||
| Altman-Z | 5.76 |
F-Score7
WACC8.38%
ROIC/WACC0.83
Cap/Depr(3y)114.54%
Cap/Depr(5y)116.58%
Cap/Sales(3y)3.77%
Cap/Sales(5y)4.81%
Profit Quality(3y)115.9%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.22%
EPS 3Y104.5%
EPS 5Y-11.43%
EPS Q2Q%-28.12%
EPS Next Y78.78%
EPS Next 2Y47.79%
EPS Next 3Y40.96%
EPS Next 5Y23.55%
Revenue 1Y (TTM)12.87%
Revenue growth 3Y15.4%
Revenue growth 5Y11.6%
Sales Q2Q%17.03%
Revenue Next Year10.4%
Revenue Next 2Y9.83%
Revenue Next 3Y6.78%
Revenue Next 5Y6.54%
EBIT growth 1Y52.68%
EBIT growth 3Y117.81%
EBIT growth 5YN/A
EBIT Next Year66.74%
EBIT Next 3Y20.18%
EBIT Next 5Y16.39%
FCF growth 1Y174.49%
FCF growth 3Y152.76%
FCF growth 5YN/A
OCF growth 1Y120.41%
OCF growth 3Y67.59%
OCF growth 5Y57.51%
BIOMARIN PHARMACEUTICAL INC / BMRN FAQ
Can you provide the ChartMill fundamental rating for BIOMARIN PHARMACEUTICAL INC?
ChartMill assigns a fundamental rating of 7 / 10 to BMRN.
What is the valuation status for BMRN stock?
ChartMill assigns a valuation rating of 8 / 10 to BIOMARIN PHARMACEUTICAL INC (BMRN). This can be considered as Undervalued.
Can you provide the profitability details for BIOMARIN PHARMACEUTICAL INC?
BIOMARIN PHARMACEUTICAL INC (BMRN) has a profitability rating of 8 / 10.
What is the financial health of BIOMARIN PHARMACEUTICAL INC (BMRN) stock?
The financial health rating of BIOMARIN PHARMACEUTICAL INC (BMRN) is 7 / 10.
What is the expected EPS growth for BIOMARIN PHARMACEUTICAL INC (BMRN) stock?
The Earnings per Share (EPS) of BIOMARIN PHARMACEUTICAL INC (BMRN) is expected to grow by 78.78% in the next year.